SB 221

Drug Profile

SB 221

Alternative Names: SB-221; Tensostat

Latest Information Update: 09 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SunTen Phytotech
  • Developer Lumosa Therapeutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cardiovascular disorders

Highest Development Phases

  • Discontinued Cardiovascular disorders; Dyslipidaemias; Essential hypertension

Most Recent Events

  • 08 Sep 2017 Discontinued - Phase-II for Cardiovascular disorders in Taiwan (PO)
  • 08 Sep 2017 Discontinued - Phase-II for Dyslipidaemias in Taiwan (PO)
  • 08 Sep 2017 Discontinued - Phase-II for Essential hypertension in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top